Mike McCully, Gate Neurosciences CEO
Dragged by PhIII flop and shelved by AbbVie, a class of depression drugs finds new life at startup
A month before Allergan revealed that it would be bought out by AbbVie for $63 billion, CEO Brent Saunders took a painful hit on one …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
